In a $31 million development agreement with Emergent BioSolutions announced Monday, the Department of Health and Human Services said it will fund Phase III development for NuThrax, Emergent's new anthrax vaccine that's already been funded through Phase I and II by the NIH and the Department of Defense.
The U.S. Department of Health and Human Services apparently likes what it's seen from a 5-year contract with VaxInnate. Its Biomedical Advanced Research and Development Authority (BARDA) has extended the contract's base period with the flu vaccine maker, a move that allows for the use of $53 million.
One of three manufacturing sites commissioned by the Department of Health and Human Services to quickly develop and produce flu vaccines in the case of a pandemic is expected to be fully operational by 2017, officials say.
In response to concerns about biodefense, the Department of Health and Human Services is helping GlaxoSmithKline and Texas A&M build a $91 million vaccine production plant.
Novavax saw a climb in its share value on the announcement that it has started enrollment of a Phase I clinical trial of its A/H5N1 vaccine to prevent bird flu.